The commensal microbiome has been shown to exhibit intimate associations with human health and diseases.Harboring abundant microbes,the gut is involved in regulating the physical and pathological status of liver,inclu...The commensal microbiome has been shown to exhibit intimate associations with human health and diseases.Harboring abundant microbes,the gut is involved in regulating the physical and pathological status of liver,including hepatic function,inflammation,immunity,metabolism,regeneration,etc.(1,2).Although it has been proposed in the gut-liver axis theory that the gut microbes and their metabolites could be disseminated into liver through the portal vein system,particularly in the conditions of gut microbiota dysbiosis and intestinal barrier dysfunction(3),the liver microbiome has only been confirmed and characterized in recent years.In this article,we reviewed the latest research advancements pertaining to the liver microbiome,discussed its potential clinical implications,and further explored the promising avenues for future research in this field(Figure 1).展开更多
Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine[1].Poor prognosis of cancer is mainly caused by a lack of effective treatment.Moreover,...Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine[1].Poor prognosis of cancer is mainly caused by a lack of effective treatment.Moreover,many patients cannot receive appropriate treatment despite early diagnosis.High heterogeneity is a tumor characteristic and different types of cancer usually vary in clinical features and tumorigenic mechanisms,which results in different responses to drugs[2].How to predict accurately the patient’s response to drugs and choose personalized treatment is one of themain concerns of doctors.展开更多
The human digestive tract is home to trillions of microbes,and owing to the advent of next-generation sequencing at the turn of the century and the development of bioinformatics technology,researchers have been able t...The human digestive tract is home to trillions of microbes,and owing to the advent of next-generation sequencing at the turn of the century and the development of bioinformatics technology,researchers have been able to unravel the picture of the gut microbiome(1).展开更多
In the past decade, sorafenib has been the only approved molecular-targeted agent for unresectable hepatocellular carcinoma (uHCC) without any authentic challenges. There has been an urging need for alternatives or su...In the past decade, sorafenib has been the only approved molecular-targeted agent for unresectable hepatocellular carcinoma (uHCC) without any authentic challenges. There has been an urging need for alternatives or superior options for a long while (1-3). At least 25 molecular-targeted drugs emerged in the past 15 years and had been tested for the efficacy and safety in treating uHCC, yet most of those trials have failed to show positive results (Table 1).展开更多
基金Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)(No.2021-I2M-1-058).
文摘The commensal microbiome has been shown to exhibit intimate associations with human health and diseases.Harboring abundant microbes,the gut is involved in regulating the physical and pathological status of liver,including hepatic function,inflammation,immunity,metabolism,regeneration,etc.(1,2).Although it has been proposed in the gut-liver axis theory that the gut microbes and their metabolites could be disseminated into liver through the portal vein system,particularly in the conditions of gut microbiota dysbiosis and intestinal barrier dysfunction(3),the liver microbiome has only been confirmed and characterized in recent years.In this article,we reviewed the latest research advancements pertaining to the liver microbiome,discussed its potential clinical implications,and further explored the promising avenues for future research in this field(Figure 1).
基金supported by grants from the CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2016-I2M-1–001)and the National High-tech Research and Development Projects(863)(No.2015AA020303).
文摘Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine[1].Poor prognosis of cancer is mainly caused by a lack of effective treatment.Moreover,many patients cannot receive appropriate treatment despite early diagnosis.High heterogeneity is a tumor characteristic and different types of cancer usually vary in clinical features and tumorigenic mechanisms,which results in different responses to drugs[2].How to predict accurately the patient’s response to drugs and choose personalized treatment is one of themain concerns of doctors.
基金This study was supported by grants from the National Natural Science Foundation of China(No.82273406)the Natural Science Foundation of Jiangsu Province(No.BK20211378).
文摘The human digestive tract is home to trillions of microbes,and owing to the advent of next-generation sequencing at the turn of the century and the development of bioinformatics technology,researchers have been able to unravel the picture of the gut microbiome(1).
文摘In the past decade, sorafenib has been the only approved molecular-targeted agent for unresectable hepatocellular carcinoma (uHCC) without any authentic challenges. There has been an urging need for alternatives or superior options for a long while (1-3). At least 25 molecular-targeted drugs emerged in the past 15 years and had been tested for the efficacy and safety in treating uHCC, yet most of those trials have failed to show positive results (Table 1).
